MIM
NGNE icon

MetLife Investment Management’s Neurogene NGNE Stock Holding History

MetLife Investment Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Hold
5,932
– – ﹤0.01% 2458
2025
Q4 		$122K Hold
5,932
– – ﹤0.01% 2515
2025
Q3 		$103K Hold
5,932
– – ﹤0.01% 2639
2025
Q2 		$88.7K Sell
5,932
-122
-2% -$1.91K ﹤0.01% 2609
2025
Q1 		$70.9K Hold
6,054
– – ﹤0.01% 2643
2024
Q4 		$138K Hold
6,054
– – ﹤0.01% 2477
2024
Q3 		$254K Buy
+6,054
New +$235K ﹤0.01% 2162
2021
Q4 		– Sell
-218
Closed -$31.6K – 2533
2021
Q3 		$31.6K Sell
218
-510
-70% -$78.1K ﹤0.01% 2553
2021
Q2 		$134K Buy
728
+537
+281% +$119K ﹤0.01% 2364
2021
Q1 		$47K Sell
191
-548
-74% -$140K ﹤0.01% 2285
2020
Q4 		$208K Hold
739
– – ﹤0.01% 1964
2020
Q3 		$177K Hold
739
– – ﹤0.01% 1931
2020
Q2 		$245K Buy
+739
New +$193K ﹤0.01% 1780

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

MetLife Investment Management's NGNE Position: Q1 2026 in Review

MetLife Investment Management held its Neurogene (NGNE) position steady in Q1 2026 at 5,932 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

MetLife Investment Management first reported a position in NGNE in Q2 2020 and has held it in 13 quarters since. The position peaked at $254K in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • MetLife Investment Management held 5,932 shares of Neurogene worth $120K as of Q1 2026.
  • MetLife Investment Management left its Neurogene share count unchanged in Q1 2026.
  • Neurogene made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2458 holding.
  • MetLife Investment Management first reported a position in Neurogene in Q2 2020 and has held it in 13 quarters since.
  • MetLife Investment Management's Neurogene position peaked at $254K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.